Item 7.01 Regulation FD Disclosure.
Cara Therapeutics, Inc. (the "Company") updated its corporate presentation,
which has been posted on its website and will be used for presentations. The
corporate presentation was updated to include the previously announced top-line
data from the Company's Phase 2 clinical trial of Oral KORSUVA for chronic
kidney disease-associated pruritus, as well as its recently completed additional
prespecified analyses, which showed statistically significant differences
between Oral KORSUVA and placebo in percentage of Numeric Rating Scale complete
responders at Week 12 and percentage of patients scoring "much improved" or
"very much improved" Patient Global Impression of Change at Week 12.
A copy of the presentation is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated herein by reference.
The information furnished under this Item 7.01, including Exhibit 99.1, shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or subject to the liabilities of that section. The
information shall not be deemed incorporated by reference into any other filing
with the Securities and Exchange Commission made by the Company, regardless of
any general incorporation language in such filing.
© Edgar Online, source Glimpses
CARA THERAPEUTICS, INC. 
